Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsTerminated
NCT03871348Phase 1Updated Sep 10, 2025
Sponsor: Sanofi
Metastatic Neoplasm
United States, Belgium, France, Germany, Netherlands +1 more
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic DermatitisCompleted
NCT04992546Phase 2Updated Sep 10, 2025
Sponsor: Principia Biopharma, a Sanofi Company
Atopic Dermatitis
United States, Canada
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompleted
NCT00532155Phase 3Updated Sep 10, 2025
Sponsor: Sanofi
Carcinoma · Non Small Cell Lung
United States, Argentina, Australia, Austria, Brazil +27 more
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)Completed
NCT04669600Phase 2Updated Sep 10, 2025
Sponsor: Bioverativ, a Sanofi company
Immune Thrombocytopenia (ITP)
United States, Czechia, Germany, Netherlands, Spain +1 more
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)Completed
NCT04681729Phase 3Updated Sep 10, 2025
Sponsor: Sanofi
Cold Urticaria
United States, Argentina, Canada, Germany, Japan
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe AsthmaCompleted
NCT04400318Phase 4Updated Sep 9, 2025
Sponsor: Sanofi
Asthma
United States, Bulgaria, Denmark, France, Italy +8 more
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.Completed
NCT05513053Phase 3Updated Sep 9, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization
United States, Czechia, Poland, Spain
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaTerminated
NCT03860844Phase 2Updated Sep 9, 2025
Sponsor: Sanofi
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia
United States, Argentina, Brazil, Denmark, France +11 more
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 YearsTerminated
NCT05513391Phase 3Updated Sep 9, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization
United States, Poland, Spain
Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia GravisTerminated
NCT05132569Phase 3Updated Sep 9, 2025
Sponsor: Sanofi
Myasthenia Gravis
United States, Canada, China, Hungary, Italy +4 more
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersCompleted
NCT04491877Phase 1, Phase 2Updated Sep 9, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infection
United States, Chile, Honduras
A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic RhinitisCompleted
NCT05692154Phase 3Updated Sep 9, 2025
Sponsor: Opella Healthcare Group SAS, a Sanofi Company
Seasonal Allergic Rhinitis
Canada
Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back PainCompleted
NCT05137041Phase 3Updated Sep 9, 2025
Sponsor: Sanofi
Low Back Pain
Germany, Italy
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusCompleted
NCT05114590Phase 4Updated Sep 9, 2025
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal ImpairmentTerminated
NCT05552859Phase 4Updated Sep 8, 2025
Sponsor: Sanofi
Type 2 Diabetes Mellitus · Renal Impairment
United States, Czechia, Hungary, Poland, Serbia
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompleted
NCT04398706Phase 2Updated Sep 8, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Pneumococcal Immunisation · Diphtheria Immunisation · Tetanus Immunisation · Pertussis Immunisation
United States, Canada, Honduras, Puerto Rico
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.Completed
NCT04583618Phase 2Updated Sep 8, 2025
Sponsor: Sanofi
Pneumococcal Immunization
United States
A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy ParticipantsCompleted
NCT06342700Phase 1Updated Sep 3, 2025
Sponsor: Sanofi
Autoimmune Disorder · Healthy Volunteers
United States
Clinical Trial to Assess the Influenza Vaccination (FLUVAC 02)Completed
NCT01764152NAUpdated Sep 2, 2025
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Adult Hospitalized
France
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEATerminated
NCT05245071Phase 2Updated Aug 29, 2025
Sponsor: Sanofi
Non-squamous Non-small Cell Lung Cancer
United States, Belgium, France, Italy, Japan +2 more
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus ErythematosusCompleted
NCT04781816Phase 2Updated Aug 27, 2025
Sponsor: Sanofi
Cutaneous Lupus Erythematosus
United States, Argentina, Australia, Canada, Chile +10 more
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological MalignanciesTerminated
NCT06508489Phase 1, Phase 2Updated Aug 22, 2025
Sponsor: Sanofi
Acute Myeloid Leukemia
United States, Australia
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric CancerTerminated
NCT05071053Phase 2Updated Aug 22, 2025
Sponsor: Sanofi
Adenocarcinoma Gastric · Gastrooesophageal Cancer
Belgium, Japan, Russia, South Korea, Spain +1 more
Screening Adults With Obesity to Reduce Heart Failure EventsActive Not Recruiting
NCT06137261NAUpdated Aug 21, 2025
Sponsor: Franciscus Gasthuis
Obesity · Heart Failure
Netherlands
Kuwait Heart Foundation Registry of Acute Coronary EventsCompleted
NCT05857735N/AUpdated Aug 20, 2025
Sponsor: Gulf Heart Association
ACS
Kuwait

Previous page Next page